Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents


Por: Angelergues A, Efstathiou E, Gyftaki R, Wysocki P, Lainez N, Gonzalez I, Castellano D, Ozguroglu M, Carbonero I, Flechon A, Borrega P, Guillot A, Balea B, Le Moulec S, Esteban E, Munarriz J, Rubio G, Birtle A, Delanoy N, Bellmunt J, Oudard S

Publicada: 1 ago 2018
Resumen:
Several agents have demonstrated an overall survival (OS) benefit in metastatic castration-resistant prostate cancer (mCRPC); however, optimal sequencing is unknown. Retrospective analysis of data from 574 mCRPC patients showed increasing OS with the number of therapies provided; a sequence including docetaxel, cabazitaxel (CABA), and an androgen receptor-targeted agent (ART) provided the greatest benefit. Prior administration of ART did not appear to influence CABA activity. These findings will help guide treatment decisions in daily practice. Background: Several agents have demonstrated an overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC); however, the optimal sequencing of these therapies is unknown as a result of a lack of prospective randomized controlled trials. This retrospective study aimed to identify clinical factors influencing outcomes and to determine optimal treatment sequencing in patients with mCRPC treated with cabazitaxel (CABA) and/or androgen receptor-targeted agents (ART) after androgen-deprivation therapy (ADT) and docetaxel (DOC). Patients and Methods: Records of 574 consecutive patients treated (2012-2016) at 44 centers in 6 countries were retrospectively examined. Results: A total of 267 patients received ADT -> DOC -> CABA (group 1), 183 patients ADT -> DOC -> ART -> CABA (group 2), and 124 patients ADT -> DOC -> CABA -> ART (group 3), with respective median OS from diagnosis of mCRPC of 38.3, 44.45, and 53.9 months (P = .012 for group 3 vs. group 1). Multivariate analysis showed response to first ADT <= 12 months, Gleason score of 8 to 10, clinical progression, and high prostate-specific antigen levels at mCRPC diagnosis were associated with worse OS. Prior receipt of ART did not influence activity of CABA. Conclusion: OS appeared to increase with the number of life-extending therapies, with a sequence including DOC, CABA, and an ART providing the greatest OS benefit.

Filiaciones:
Angelergues A:
 Georges Pompidou European Hosp, Dept Med Oncol, Paris, France

Efstathiou E:
 Univ Athens, Alexandra Gen Hosp Athens, Athens, Greece

Gyftaki R:
 Univ Athens, Alexandra Gen Hosp Athens, Athens, Greece

Wysocki P:
 M Sklodowska Curie Mem Canc Ctr Inst, Warsaw, Poland

Lainez N:
 Complejo Hosp Navarra, Pamplona, Spain

Gonzalez I:
 Univ Hosp Mar IMIM, Barcelona, Spain

Castellano D:
 Hosp Univ 12 Octubre, Madrid, Spain

Ozguroglu M:
 Istanbul Univ, Istanbul, Turkey

Carbonero I:
 Hosp Virgen de la Salud, Med Oncol Dept, Toledo, Spain

Flechon A:
 Ctr Leon Berard, Lyon, France

Borrega P:
 Hosp San Pedro de Alcantara, Caceres, Spain

Guillot A:
 Inst Cancerol Loire, St Etienne, France

Balea B:
 Hosp Univ Lucus Augusti, Lugo, Spain

Le Moulec S:
 Val de Grace Hosp, Paris, France

Esteban E:
 Hosp Univ Cent Asturias, Oviedo, Spain

Munarriz J:
 Hosp Prov Castellon, Castellon de La Plana, Spain

Rubio G:
 Hosp Univ Fdn Jimenez Diaz, Oncol Dept, Madrid, Spain

Birtle A:
 Royal Preston Hosp, Rosemere Canc Ctr, Preston, Lancs, England

Delanoy N:
 Georges Pompidou European Hosp, Dept Med Oncol, Paris, France

Bellmunt J:
 Univ Hosp Mar IMIM, Barcelona, Spain

Oudard S:
 Georges Pompidou European Hosp, Dept Med Oncol, Paris, France

 Univ Paris 05, Sorbonne Paris Cite, Paris, France
ISSN: 15587673





Clinical Genitourinary Cancer
Editorial
CIG MEDIA GROUP, LP, 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 16 Número: 4
Páginas: 777-784
WOS Id: 000439486400010
ID de PubMed: 29550200

MÉTRICAS